Citations

Clear

2960 citation(s) found for "Kim, P".

Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma
Sekulić, Aleksandar , Kim, Su Y. , Savage, Stephanie, Einspahr, Janine G., Prasad, Anil , Sagerman, Paul, Curiel‐Lewandrowski, Clara , Bowden, G. Timothy, Warneke, James, Alberts, David S., Pittelkow, Mark R. , DiCaudo, David J. , Nickoloff, Brian J. , Trent, Jeffrey M. , Bittner, Michael , Hostetter, Galen H. , Krouse, Robert S.

Mayo Clinic

Cancer Prevention Research | September 28, 2010 | Volume: 3 | Issue: 10 | Pages: 1277-1283

10.1158/1940-6207.capr-10-0058 | PMID 20876729 Get It

Abstract Cutaneous squamous cell carcinoma (SCC) occurs commonly and can metastasize. Identification of specific molecular aberrations and mechanisms underlying the development and progression of cutaneous SCC may lead to better prognostic and therapeutic approaches and more effective chemoprevention strategies. To identify genetic changes associated with early stages of cutaneous SCC development, we analyzed a series of 40 archived skin tissues ranging from normal skin to invasive SCC. Using high-resolution array-based comparative genomic hybridization, we identified deletions of a region on chromosome 10q harboring the INPP5A gene in 24% of examined SCC tumors. Subsequent validation by immunohistochemistry on an independent sample set of 71 SCC tissues showed reduced INPP5A protein levels in 72% of primary SCC tumors. Decrease in INPP5A protein levels seems to be an early event in SCC development, as it also is observed in 9 of 26 (35%) examined actinic keratoses, the earliest stage in SCC development. Importantly, further reduction of INPP5A levels is seen in a subset of SCC patients as the tumor progresses from primary to metastatic stage. The observed frequency and pattern of loss indicate that INPP5A, a negative regulator of inositol signaling, may play a role in development and progression of cutaneous SCC tumors. Cancer Prev Res; 3(10); 1277–83. ©2010 AACR.
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
Tallman, Martin S. , Montesinos, Pau , Appelbaum, Frederick R. , Serna, Javier de la , Bennett, John M. , Debén, Guillermo, Bloomfield, Clara D. , González, José D. , Feusner, James H., González, Marcos , Gallagher, Robert E. , Miguel, José D. González‐San, Larson, Richard A. , Paietta, Elisabeth , Rayón, Chelo, Rowe, Jacob M. , Rivas, Concha, Schiffer, Charles A. , Vellenga, Edo , Shepherd, Lois E. , Slack, James L., Wiernik, Peter H. , Sanz, Miguel Á. , Kim, Haesook T. , Milone, Giuseppe , Willman, Cheryl L. , Larson, Richard A , Montesinos, Pau

Mayo Clinic

Blood | September 22, 2010 | Volume: 116 | Issue: 25 | Pages: 5650-5659

10.1182/blood-2010-06-288613 | PMID 20858857 Get It

Abstract Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era. Here, the outcome of 155 patients treated with all-trans retinoic acid–based therapy on 3 clinical trials, North American Intergroup protocol I0129 and Programa para el Estudio de la Terapéutica en Hemopatía Maligna protocols LPA96 and LPA99, are reported. The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% compared with 8.4% for patients with classical M3 morphology. With a median follow-up time among survivors of 7.6 years (range 3.6-14.5), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse for patients with M3V were 70%, 73%, and 24%, respectively. With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80% (P = .006 compared with M3V), 81% (P = .07), and 15% (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.
Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries
Bhatt, Deepak L. , Steg, Philippe Gabríel , Ohman, E. Magnus, Corbalán, Ramón, Eagle, Kim A., Gaxiola, Efraín, Gao, Runlin, Goto, Shinya , Smith, Sidney C. , Wilson, Peter W.F. , Investigators, for the Reduction of Atherothrombosis for Continued Health (REACH) Registry, Goyal, Abhinav , Gersh, Bernard J. , Alberts, Mark J. , D’Agostino, Ralph B. , Califf, Robert M. , Investigators, for the Reduction of Atherothrombosis for Continued Health (REACH) Registry, Bhatt, Deepak L , Steg, P Gabriel

Mayo Clinic

Circulation | September 8, 2010 | Volume: 122 | Issue: 12 | Pages: 1167-1175

10.1161/circulationaha.109.919274 | PMID 20823388 Get It

Background— Studies report a protective effect of higher attained educational level (AEL) on cardiovascular outcomes. However, most of these studies have been conducted in high-income countries (HICs) and lack representation from low- and middle-income countries (LMICs), which bear >80% of the global burden of cardiovascular disease. Methods and Results— The Reduction of Atherothrombosis for Continued Health (REACH) Registry is a prospective study of 67 888 subjects with either established atherothrombotic (coronary, cerebrovascular, and/or peripheral arterial) disease or multiple atherothrombotic risk factors enrolled from 5587 physician practices in 44 countries. At baseline, AEL (0 to 8 years, 9 to 12 years, trade or technical school, and university) was self-reported for 61 332 subjects. Outcomes included the baseline prevalence of atherothrombotic risk factors and the rate of incident cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) through 23 months across AEL groups, stratified by sex and world region (LMICs or HICs). Educational attainment was inversely associated with age and diabetes mellitus and directly associated with hypercholesterolemia in all subjects. However, for other risk factors such as obesity, smoking, hypertension, and baseline burden of vascular disease, AEL was protective (inversely associated) in HICs but not protective in LMICs. The protective effect of greater AEL on incident cardiovascular events was strongest in men from HICs ( P <0.0001), more modest in women from HICs ( P =0.0026) and in men from LMICs ( P =0.082), and essentially absent in women from LMICs ( P =0.32). Conclusion— In contrast to HICs, higher AEL may not be protective against cardiovascular events in LMICs, particularly in women.
Polymorphisms in the Matrilin-1 Gene and Risk of Mandibular Prognathism in Koreans
Jang, Jin‐Sung, Park, E.K., Ryoo, Hyun‐Mo , Shin, Hong‐In , Kim, T.H., Jang, Jin Sung , Park, Hyeon-Bin, Choi, Ji‐won, Kwon, Tae‐Geon

Mayo Clinic

Journal of Dental Research | August 25, 2010 | Volume: 89 | Issue: 11 | Pages: 1203-1207

10.1177/0022034510375962 | PMID 20739701 Get It

Previous linkage analysis of an Asian population proposed possible candidate genes for mandibular prognathism, such as Matrilin-1 (cartilage matrix protein). To investigate the association between the single-nucleotide polymorphisms (SNPs) in Matrilin-1 and mandibular prognathism, we investigated three sequence variants (-158 T>C, 7987 G>A, 8572 C>T) in 164 mandibular prognathism patients and 132 control individuals with a normal occlusion. The results showed that the 8572 TT genotypes in Matrilin-1 showed increased risk of mandibular prognathism (OR = 9.28, 95% Cl = 1.19~197.57, P < 0.05), whereas the 7987 AA genotype showed a protective effect for mandibular prognathism (OR = 0.16, 95% Cl = 0.05~0.47, P < 0.05). Genotyping results showed that the Matrilin-1 polymorphism haplotype TGC (ht4; 158T, 7987G, and 8572C alleles) had a pronounced risk effect for mandibular prognathism compared with controls (OR = 5.16, 95% Cl = 2.03~13.93, P < 0.01). The results suggest that polymorphisms in Matrilin-1 could be used as a marker for genetic susceptibility to mandibular prognathism.
Decursin Prevents Cisplatin-Induced Apoptosis via the Enhancement of Antioxidant Enzymes in Human Renal Epithelial Cells
Kim, Jeong Hwan , Jeong, Soo‐Jin , Kwon, Hee Young , Lee, Hyo‐Jeong , Kim, Sung‐Hoon , Park, Sang Yoon , Lee, Hyo‐Jung , Lieske, John C.

Mayo Clinic

Biological and Pharmaceutical Bulletin | August 2, 2010 | Volume: 33 | Issue: 8 | Pages: 1279-1284

10.1248/bpb.33.1279 | PMID 20686219 Get It

Development of intraoperative electrochemical detection: wireless instantaneous neurochemical concentration sensor for deep brain stimulation feedback
Chang, Su-Youne , Goerss, Stephan J., Kimble, Christopher J., Bennet, Kevin E. , Lee, Kendall H. , Gompel, Jamie J. Van , Kim, In

Mayo Clinic

Neurosurgical Focus | July 30, 2010 | Volume: 29 | Issue: 2 | Pages: E6

10.3171/2010.5.focus10110 | PMID 20672923 Get It

Deep brain stimulation (DBS) is effective when there appears to be a distortion in the complex neurochemical circuitry of the brain. Currently, the mechanism of DBS is incompletely understood; however, it has been hypothesized that DBS evokes release of neurochemicals. Well-established chemical detection systems such as microdialysis and mass spectrometry are impractical if one is assessing changes that are happening on a second-to-second time scale or for chronically used implanted recordings, as would be required for DBS feedback. Electrochemical detection techniques such as fast-scan cyclic voltammetry (FSCV) and amperometry have until recently remained in the realm of basic science; however, it is enticing to apply these powerful recording technologies to clinical and translational applications. The Wireless Instantaneous Neurochemical Concentration Sensor (WINCS) currently is a research device designed for human use capable of in vivo FSCV and amperometry, sampling at subsecond time resolution. In this paper, the authors review recent advances in this electrochemical application to DBS technologies. The WINCS can detect dopamine, adenosine, and serotonin by FSCV. For example, FSCV is capable of detecting dopamine in the caudate evoked by stimulation of the subthalamic nucleus/substantia nigra in pig and rat models of DBS. It is further capable of detecting dopamine by amperometry and, when used with enzyme linked sensors, both glutamate and adenosine. In conclusion, WINCS is a highly versatile instrument that allows near real-time (millisecond) detection of neurochemicals important to DBS research. In the future, the neurochemical changes detected using WINCS may be important as surrogate markers for proper DBS placement as well as the sensor component for a “smart” DBS system with electrochemical feedback that allows automatic modulation of stimulation parameters. Current work is under way to establish WINCS use in humans.
Rationale for Complementary and Alternative Medicine in Nursing School Curriculum
Moore, Kim

Mayo Clinic

The Journal of Alternative and Complementary Medicine | June 22, 2010 | Volume: 16 | Issue: 6 | Pages: 611-612

10.1089/acm.2009.0629 | PMID 20569024 Get It

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
Lubner, Sam Joseph , Mahoney, Michelle R., Kolesar, Jill L., LoConte, Noelle K. , Kim, George P., Pitot, Henry C., Yong, Wei Peng , Horvath, Lisa G. , Hazel, Guy van , Erlichman, Charles , Holen, Kyle D., Kolesar, Jill L., Philip, Philip A. , Picus, Joel , LoConte, Noelle , Yong, Wei-Peng , Lubner, Sam J

Mayo Clinic

Journal of Clinical Oncology | June 8, 2010 | Volume: 28 | Issue: 21 | Pages: 3491-3497

10.1200/jco.2010.28.4075 | PMID 20530271 Get It

PurposeBiliary cancers overexpress epidermal growth factor receptor (EGFR), and angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor have each been shown to have activity in biliary cancer. The primary objective of this study was to evaluate the response rate by Response Evaluation Criteria in Solid Tumors (RECIST). Secondary end points included overall survival (OS), time to progression (TTP), VEGF levels, and molecular studies of EGFR and k-ras.Patients and MethodsEligible patients had advanced cholangiocarcinoma or gallbladder cancer. Patients were treated with bevacizumab 5 mg/kg intravenously on days 1 and 15 and erlotinib 150 mg by mouth daily on days 1 through 28. Responses were evaluated by RECIST. VEGF levels were collected, and samples were analyzed for EGFR mutation by polymerase chain reaction.ResultsFifty-three eligible patients were enrolled at eight sites. Of 49 evaluable patients, six (12%; 95% CI, 6% to 27%) had a confirmed partial response. Stable disease was documented in another 25 patients (51%). Rash was the most common grade 3 toxicity. Four patients had grade 4 toxicities. Median OS was 9.9 months, and TTP was 4.4 months. Low repeats (< 16) in EGFR intron 1 polymorphism and G>G k-ras Q38 genotype (wild type) were associated with improved outcomes.ConclusionCombination chemotherapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse effects in patients with advanced biliary cancers. On the basis of preliminary molecular analysis, presence of a k-ras mutation may alter erlotinib efficacy. The combination of bevacizumab and erlotinib may be a therapeutic alternative in patients with advanced biliary cancer.
Diffusion-Weighted MRI at 3 T for the Evaluation of Prostate Cancer
Kim, Chan Kyo , Park, Byung Kwan , Kim, Bohyun

Mayo Clinic

American Journal of Roentgenology | May 20, 2010 | Volume: 194 | Issue: 6 | Pages: 1461-1469

10.2214/ajr.09.3654 | PMID 20489084 Get It